Company: PSTV
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-178940
Chunk: 4

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-08-12
Form: S-1
Chunk 4
---
 | 14 |
| DILUTION                                                                            |     | 16 |
| THE SELLING STOCKHOLDER                                                             |     | 17 |
| MARKET PRICE OF OUR COMMON STOCK AND RELATED STOCKHOLDER                            
 MATTERS                                                                             |     | 19 |
| DESCRIPTION OF CAPITAL STOCK                                                        |     | 20 |
| PLAN OF DISTRIBUTION                                                                |     | 25 |
| LEGAL MATTERS                                                                       |     | 27 |
| EXPERTS                                                                             |     | 27 |
| WHERE YOU CAN FIND MORE INFORMATION                                                 |     | 27 |
| INCORPORATION BY REFERENCE                                                          |     | 28 |
| DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES |     | 29 |

i

ABOUT THIS PROSPECTUS

This prospectus forms part of a registration statement that we filed with the Securities and Exchange Commission (the “SEC”), and
that includes exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus and the related exhibits filed with the SEC, together with the additional information described under the headings
“Where You Can Find More Information” and “Incorporation by Reference” before making your investment decision.

You should rely only on the information provided in this prospectus or in a prospectus supplement or any free writing prospectuses or
amendments thereto. Neither we, nor the selling stockholder, have authorized anyone else to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. You should assume that
the information in this prospectus is accurate only as of the date hereof. Our business, financial condition, results of operations and prospects may have changed since that date.

Neither we, nor the selling stockholder, are offering to sell or seeking offers to purchase these securities in any jurisdiction where the
offer or sale is not permitted. We have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons
outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities as to distribution of the prospectus outside of the United States.

Unless the context otherwise requires, references in this prospectus to “Plus,” “the Company,” “we,”
“us” and “our” refer to Plus Therapeutics, Inc.